Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653224 | 0.94 | MAOB (0.59) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL2957360 | 0.94 | HDAC1 (0.57) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL1047276 | 0.92 | HDAC1 (0.56) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL4089161 | 0.92 | HDAC1 (0.56) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL1079525 | 0.92 | HDAC1 (0.56) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL23176839 | 0.92 | HDAC1 (0.56) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL2652908 | 0.88 | MAOB (0.58) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL30357697 | 0.87 | TAAR1 (0.44) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL2652794 | 0.87 | MAOB (0.56) | TAAR1HDAC1HDAC8MAOBPTPN2 | |
| SCHEMBL2653733 | 0.87 | MAOB (0.56) | TAAR1HDAC1HDAC8MAOBPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361249-A1 | SURFACE TREATMENT AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| EP-4644398-A1 | SURFACE TREATMENT AGENT | Daikin Industries, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-25 | — | — | US | disclosed |
| CN-119285657-A | Method for synthesizing alkyl borate compound by taking allyl alcohol as substrate | 河南大学 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024172036-A1 | SURFACE TREATMENT AGENT | ダイキン工業株式会社 | 2024-08-22 | — | — | WO | disclosed |
| CN-113272285-B | Oxadiazole-containing compound and pharmaceutical composition containing same | 爱思开生物制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023237580-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2023-12-14 | — | — | WO | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| WO-2007122591-A2 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122591-A2 | PYRAZOLO-TETRAHYDRO PYRIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2006112565-A1 | THERAPEUTIC DRUGS FOR POLLAKIURIA AND URINARY INCONTINENCE CONTAINING OPTICAL ACTIVE PROPIOPHENON AND ITS SALTS | DREAMPHARMA CORP. (KR) | 2006-10-26 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1517881-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | Syngenta Participations AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| US-5760245-A | FUNGICIDES | J. URIACH & CIA S.A. (ES) | 1998-06-02 | — | — | US | disclosed |
| EP-0801071-A1 | LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | TAAR1 1734/4885HDAC1 1189/4885HDAC8 2288/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TAAR1 364/4885HDAC1 322/4885HDAC8 993/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TAAR1 3009/4885HDAC1 2416/4885HDAC8 1203/4885 |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | ITGA1, ITGB1, GDI1 | TAAR1 417/4885HDAC1 140/4885HDAC8 1056/4885 |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | TALDO1, TBCA, TBCD | TAAR1 1526/4885HDAC1 216/4885HDAC8 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.